Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment
Abstract Immune-checkpoint targeting Drug Conjugates (IDCs) are a novel class of therapeutics that combine an immune checkpoint-targeting moiety, a cleavable linker, and a cytotoxic payload. By integrating features and functions of antibody-drug conjugates and immunotherapy, IDCs represent a promisi...
Saved in:
| Main Authors: | Silvia Marchesi, Arianna Marinello, Paolo Ambrosini, Chiara Cavalli, Giuseppe Lo Russo, Mario Occhipinti |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Portfolio
2025-07-01
|
| Series: | npj Precision Oncology |
| Online Access: | https://doi.org/10.1038/s41698-025-01011-7 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Resveratrol—A Promising Therapeutic Agent with Problematic Properties
by: Lyubomira Radeva, et al.
Published: (2025-01-01) -
Hydroxytyrosol: A Promising Therapeutic Agent for Mitigating Inflammation and Apoptosis
by: Wafa Ali Batarfi, et al.
Published: (2024-11-01) -
Inorganic nanomaterials as promising therapeutic agents for ocular neovascularization: Progress and perspectives
by: Yizhuo Geng, et al.
Published: (2025-08-01) -
Antibody-Drug Conjugates in Ovarian Cancer: Promises and Challenges
by: Marta Nerone, et al.
Published: (2023-10-01) -
Potential of Quercetin as a Promising Therapeutic Agent Against Type 2 Diabetes
by: Przemysław Niziński, et al.
Published: (2025-07-01)